# A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)

> **NCT03899610** · PHASE2 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 24 (estimated)

## Conditions studied

- Ovarian Cancer Stage IIIC
- Ovarian Cancer Stage IV

## Interventions

- **DRUG:** Neoadjuvant chemotherapy+Durvalumab+Tremelimumab

## Key facts

- **NCT ID:** NCT03899610
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-04
- **Primary completion:** 2021-05
- **Final completion:** 2021-05
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2020-09-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03899610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03899610, "A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03899610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*